Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
  • Patent number: 10660966
    Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 26, 2020
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Torgrim Engell, Julian Grigg, Dimitrios Mantzilas, Dag M. Evje
  • Patent number: 10655168
    Abstract: Compositions comprising covalently modified and mutated biotin-binding proteins, particularly biotin-binding proteins having a negative charge at physiological pH, are provided. Methods of producing such proteins are also provided, as are methods of immobilizing, sequencing, and making nucleic acids employing such proteins.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 19, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Lubomir Sebo, Leewin Chern, Thomas Linsky, Jeremiah Hanes, Erik Miller, Ying Yang, Stephen Yue
  • Patent number: 10370399
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 6, 2019
    Assignee: Genentech, Inc.
    Inventor: Thomas Pillow
  • Patent number: 10314922
    Abstract: A type of trimaleimide linkers and uses thereof are disclosed. The trimaleimide linkers can be applied for preparation of antibody-drug conjugate as shown by formula I: L-(T-A-D)n I wherein, L is an antibody, antibody fragment or protein; T is a trimaleimide linker; A is a cleavable linker group or a noncleavable linker; D is a drug; n is an integer ranging from 1 to 8.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: June 11, 2019
    Assignee: NewBio Therapeutics, Inc.
    Inventors: Nianhe Han, Deqiang An, Di Zeng, Baoxiang Wang, Hang Yang, Li Jian, Chun Yang
  • Patent number: 10280214
    Abstract: Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule?linkern)m?conjugation partner?(linkero?repeat-motif-molecule)p, wherein n and o are independently of each other and independently for each value of m and p integer values of 0 or 1, and m and p are independently of each other integer values of 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7, and wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site. Also reported are encoding nucleic acids and method for producing these repeat-motif-conjugates in mammalian cells.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: May 7, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stephan Fischer, Sabine Imhof-Jung, Erhard Kopetzki
  • Patent number: 9522958
    Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: December 20, 2016
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Leslie A. Khawli
  • Patent number: 9410044
    Abstract: Embodiments of the invention include linking agents including borate, borazine, or boronate groups and coatings and devices that incorporate such linking agents, along with related methods. Other embodiments are also included herein.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: August 9, 2016
    Assignee: SurModics, Inc.
    Inventor: Aleksey V. Kurdyumov
  • Patent number: 9155800
    Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: October 13, 2015
    Assignee: VALIANT BIOPHARMA SDN BHD
    Inventors: Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
  • Publication number: 20150147345
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 28, 2015
    Inventor: Marek Kwiatkowski
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Publication number: 20150147752
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Patent number: 9040310
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 26, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20150140684
    Abstract: A target affinity material comprising a biodegradable polymer, wherein the biodegradable polymer comprises one or more solid particles and one or more materials that specifically binds to a target, as well as related methods and kits.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 21, 2015
    Inventors: Ga-hee KIM, Hyun-ju Kang, Ye-ryoung Yong, Jong-myeon Park
  • Publication number: 20150133618
    Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2?CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.
    Type: Application
    Filed: April 22, 2013
    Publication date: May 14, 2015
    Inventors: Jesper Hanssen, Gustav Rodrigo, Tobias E Soderman
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Patent number: 9029509
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Publication number: 20150125397
    Abstract: Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.
    Type: Application
    Filed: October 6, 2014
    Publication date: May 7, 2015
    Inventors: Chee-Ho Choi, Tariq Ghayur, Ann Marshak-Rothstein, Krishna Moody
  • Publication number: 20150125454
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Application
    Filed: April 9, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • Publication number: 20150125473
    Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Inventors: John Burt, Antony Godwin, George Badescu
  • Publication number: 20150118185
    Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 30, 2015
    Inventor: Paul L. DeAngelis
  • Publication number: 20150118226
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 30, 2015
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9018357
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Publication number: 20150111788
    Abstract: The invention provides novel methods and materials for genetic and genomic analysis using single or multiplex isolation of protein-associated nucleic acids, including transposase-assisted chromatin immunoprecipitation (TAM-ChIP) and antibody-oligonucleotide proximity ligation. These methods comprise tagging and isolating chromatin or other protein-associated nucleic acids and using antibody-oligonucleotide complexes that recognize the proteins associated with such nucleic acids.
    Type: Application
    Filed: November 23, 2012
    Publication date: April 23, 2015
    Inventors: Joseph Fernandez, Mary Anne Jelinek, Brian Stanley Egan
  • Publication number: 20150104473
    Abstract: The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.
    Type: Application
    Filed: October 4, 2012
    Publication date: April 16, 2015
    Inventors: Ferdinand Antonius Ossendorp, Cornelis Johannes Maria Melief, Selina Khan, Dmitri Viktorovistj Filippov, Gijsbert Arie Van Der Marel
  • Publication number: 20150105291
    Abstract: It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventors: Hiroko HANZAWA, Takeshi SAKAMOTO, Yuji KUGE
  • Patent number: 9005625
    Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: April 14, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Zhi-Guang Wang
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Publication number: 20150094226
    Abstract: The present invention provides detailed three-dimensional structural information for the complex formed by the Nef protein and the sdAb19 antibody fragment. In addition, the present invention also provides residues which mediate the interaction between the Nef protein and the sdAb19 antibody fragment. The present invention also provides methods for identifying compounds modulating the interaction of the Nef protein and the sdAb19 antibody.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 2, 2015
    Inventors: Serge BENICHOU, Matthias GEYER, Sebastian LULF
  • Publication number: 20150093397
    Abstract: Methods to improve the success of cancer therapies that target CD37 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 2, 2015
    Inventor: Christina N. Carrigan
  • Patent number: 8992925
    Abstract: Chimeric molecules comprising receptor activator of NF-?B ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: March 31, 2015
    Assignee: Amgen Inc.
    Inventors: Paul Kostenuik, Wenyan Shen, Thomas C. Boone
  • Patent number: 8993725
    Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: March 31, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
  • Patent number: 8993345
    Abstract: A method of producing functional molecule-containing silica nanoparticles on which a biomolecule is bonded, containing the steps of: allowing silica nanoparticles containing a functional molecule and having a thiol group on a surface thereof to coexist with a linker molecule having a maleimido group and a carboxyl group in an aprotic solvent, thereby allowing formation of a thioether bond between the thiol group and the maleimido group, and obtaining functional molecule-containing silica nanoparticles on which the linker molecule is bonded; and allowing the functional molecule-containing silica nanoparticles on which the linker molecule is bonded to coexist with carbodiimide and a biomolecule having an amino group in an aqueous solvent, thereby allowing formation of an amide bond between the carboxyl group active esterified by the carbodiimide, and the amino group of the biomolecule.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Furukawa Electric Co., Ltd.
    Inventors: Hideki Aizawa, Michio Ohkubo, Masataka Nishida
  • Publication number: 20150086575
    Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.
    Type: Application
    Filed: October 15, 2014
    Publication date: March 26, 2015
    Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica Suschak
  • Patent number: 8987425
    Abstract: The invention provides a fusion protein comprising (a) a first protein comprising a polypeptide which specifically binds to Annexin A1 and (b) a second protein comprising a polypeptide which induces a cytotoxic activity of a cytotoxic lymphocyte, pharmaceutical compositions comprising the fusion protein, and methods of treating or preventing cancer by administering the pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: March 24, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventor: Jae-il Lee
  • Patent number: 8987424
    Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.
    Type: Grant
    Filed: April 13, 2008
    Date of Patent: March 24, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
  • Patent number: 8986688
    Abstract: This invention relates to fusion proteins that include a whey acidic protein (WAP) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a WAP domain-containing polypeptide, a second polypeptide, and a third polypeptide. The second and/or third polypeptides of the fusion proteins of the invention are an Fc polypeptide; an albumin polypeptide; a cytokine targeting polypeptide; or a serpin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: March 24, 2015
    Assignee: InhibRx, LLC
    Inventors: John Timmer, Brendan Eckelman, Grant B. Guenther, Peter L. Nguy, Henry Chan, Quinn Deveraux
  • Publication number: 20150079104
    Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
    Type: Application
    Filed: October 8, 2014
    Publication date: March 19, 2015
    Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Publication number: 20150079075
    Abstract: Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 19, 2015
    Applicant: CytoDyn Inc.
    Inventors: Richard Trauger, Robert Fleischaker
  • Publication number: 20150079581
    Abstract: The present invention is a test kit for rapidly diagnosing influenza according to the principles of immunochromatography, and the purpose thereof is to provide a test kit for the influenza A virus in which the sensitivity in detecting the influenza A virus is greater than in conventional test kits, and a determination of “positive” is obtained stably and with high precision at an earlier time during the onset of influenza symptoms. The present invention pertains to a kit for detecting influenza A virus, in which an antibody that is in solid phase in the chromatographic medium enters into an antigen-antibody reaction with native nuclear proteins of the influenza A virus, but in Western blots the antibody does not enter into antigen-antibody reactions with full-length nuclear proteins of the influenza A virus that have been separated using SDS-polyacrylamide gel electrophoresis.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 19, 2015
    Inventors: Hisahiko Iwamoto, Hiroko Kawamoto, Shinichi Kato
  • Patent number: 8981066
    Abstract: This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: March 17, 2015
    Assignee: Buck Institute for Research on Aging
    Inventor: Victoria V. Lunyak
  • Patent number: 8980266
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: March 17, 2015
    Assignee: InhibRx, LLC
    Inventors: Brendan Eckelman, John Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Patent number: 8980265
    Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: March 17, 2015
    Assignee: BioNTech AG
    Inventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
  • Publication number: 20150071923
    Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 12, 2015
    Inventors: Ge Wei, Gregory I. Frost, H. Michael Shepard, Christopher D. Thanos
  • Publication number: 20150072918
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Application
    Filed: March 18, 2014
    Publication date: March 12, 2015
    Applicant: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • Patent number: 8975384
    Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: March 10, 2015
    Assignee: Osaka University
    Inventor: Junichi Takagi
  • Publication number: 20150064715
    Abstract: The present invention provides methods of detecting mitochondrial dysfunction or acute kidney injury (AKI) by measuring the urinary protein levels of the ATP synthase (ATPS) beta subunit or cleavage products thereof in a subject.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Rick SCHNELLMANN, John ARTHUR, Craig BEESON
  • Publication number: 20150064181
    Abstract: The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 5, 2015
    Applicant: VALERION THERAPEUTICS, LLC
    Inventor: Dustin D. Armstrong